122306-01-8

Basic information

• Product Name: (6-BROMO-PYRIDIN-3-YL)-METHANOL
• Synonyms: (2-BROMO-PYRIDIN-5-YL)-METHANOL;(6-BROMO-PYRIDIN-3-YL)-METHANOL;2-Bromo-5-(hydroxymethyl)pyridine;6-Bromo-3-pyridinemethanol;2-Bromopyridine-5-methanol;6-BroMopyridine-3-Methanol;2-BroMo-5-pyridineMethanol, 95%;(6-BroMo-3-pyridyl)Methanol
• CAS NO: 122306-01-8
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• Product Categories: Building Blocks;Pyridine
• Mol File: 122306-01-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 48-51℃
• Boiling Point: 314.278 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.669 g/cm³
• Vapor Pressure: 0.0002mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.29±0.10(Predicted)
• CAS DataBase Reference: (6-BROMO-PYRIDIN-3-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (6-BROMO-PYRIDIN-3-YL)-METHANOL(122306-01-8)
• EPA Substance Registry System: (6-BROMO-PYRIDIN-3-YL)-METHANOL(122306-01-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 122306-01-8(Hazardous Substances Data)

Usage

Uses

2-Bromo-5-pyridinemethanol is used as a pharmaceutical intermediate.

InChI:InChI=1/C6H6BrNO/c7-6-2-1-5(4-9)3-8-6/h1-3,9H,4H2

Upstream product

• 6311-35-9 6-bromonicotinic acid 
• 101990-45-8 2-bromo-5-bromomethylpyridine 
• 26218-78-0 methyl 6-bromonicotinate 
• 35905-85-2 2-bromonicotinic acid 
• 149806-06-4 6-bromonicotinaldehyde 

Downstream Products

• 472962-10-0 2-bromo-5-[(trityloxy)methyl]pyridine 
• 1252572-53-4 (6-bromo-3-pyridyl)methyl [1-(tert-butyl)-1,1-diphenylsilyl] ether 
• 168173-56-6 2-bromo-5-pyridylmethyl chloride 
• 1126779-39-2 2-bromo-5-(chloromethyl)pyridine hydrochloride 
• 101990-45-8 2-bromo-5-bromomethylpyridine 
• 1391602-00-8 C₈H₉NO₂ 
• 1189175-81-2 [5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridin-2-yl](4-chloro-3,5-difluorophenyl)methanone 
• 432554-92-2 2-vinyl-5-hydroxymethylpyridine 
• 145733-66-0 2-Methyl-4-trifluoromethyl-5,6,8-trihydro-8-[[6-(2-cyanophenyl)-3-pyridinyl]methyl]-7H-pyrido[2,3-d]pyrimidin-7-one 
• 145733-64-8 5,8-dihydro-2,4-dimethyl-8-<<6-(2-cyanophenyl)-3-pyridinyl>methyl>pyrido<2,3-d>pyrimidin-7(6H)-one 
• 145733-55-7 2-<5-<<(tert-butyldimethylsilyl)oxy>methyl>pyridin-2-yl>benzonitrile 
• 145733-56-8 2-<5-(hydroxymethyl)pyridin-2-yl>benzonitrile 
• 145733-57-9 2-<5-(chloromethyl)pyridin-2-yl>benzonitrile 
• 472962-15-5 2-((E)-2-Iodo-propenyl)-5-trityloxymethyl-pyridine 

Relevant articles and documents

A Copper Complex of a Thiosemicarbazone-Pyridylhydrazone Ligand Containing a Vinylpyridine Functional Group as a Potential Imaging Agent for Amyloid-β Plaques

Complexes containing positron-emitting radionuclides of copper have the potential to be of use for diagnostic imaging with positron emission tomography. Alzheimer's disease is characterised by the presence of amyloid-β plaques in the brain. A new thiosemicarbazone-pyridyl hydrazone tetradentate ligand with a pyridyl-4-vinylpyridine functional group was prepared with the aim of making a copper complex that binds to amyloid-β plaques to assist in the diagnosis of Alzheimer's disease. The ligand forms a charge neutral complex with copper(ii) that was characterised by X-ray crystallography and the electrochemical behaviour of the complex was investigated by cyclic voltammetry. The new ligand can be radiolabelled with positron-emitting copper-64 at room temperature in excellent radiochemical yields. The new complex interacts with synthetic amyloid-β fibrils and binds amyloid-β plaques present in post-mortem Alzheimer's disease brain tissue.

CDK4/6 INHIBITORS AND USE THEREOF

The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.

Benzimidazole derivatives, preparation methods and uses theirof

The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.